8:00am-10:06am

PLENARY SESSION 1 - Therapy Response and Resistance - Session Chair - Corine Bertolotto
Pentland Suite

Click here to view this recording.

8:00am - 8:20am

Towards rational combination therapies: Understanding tumor evolution during therapy response and resistance  

Presented by: Anna Obenauf

8:20am - 8:35am

Loss of LYN in targeted-therapy resistant melanoma cells favors metastatic properties.
Presented by: Céline Pisibon

8:35am - 8:50am

Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma
Presented by: Claudia Capparelli

8:50am - 9:05am

CD4+ T cell-induced inflammatory killing controls immune evasive tumors
Presented by: Anthony Buzzai

9:05am - 9:20am

Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Unresectable Melanoma
Presented by: Yousef Zakharia

9:20am - 9:35am

The CD58:CD2 axis: a critical regulator of cancer immunity
Presented by: Patricia Ho

9:35am - 10:00am

Combating immunotherapy resistance – a functional genomics approach
Presented by: Daniel Peeper

10:00am - 10:06am

Flash Talks:

Implications of AMBRA1 in phenotype plasticity and response to MAPKi
Presented by: Luca Di Leo

Tumor Biomarker Analysis From COLUMBUS Part 1: Encorafenib + Binimetinib for BRAF V600E/K-Mutant Advanced or Metastatic Melanoma
Presented by: Nuzhat Pathan

10:05am - 10:30am

Refreshment Break
Cromdale Hall & Strathblane Hall

10:30am - 12:25pm

CONCURRENT SESSION 2B - Prevention and Early Detection and Biomarkers - Session Chair - Paul Lorigan
Lomond Suite

10:30am - 10:50am

Tailoring skin check recommendations according to personal risk: acceptability, feasibility and fidelity
Presented by: Anne Cust

10:50am - 11:05pm

Primary melanoma prevention: effectiveness of sunscreen application counseling
Presented by: Maria Wei

11:05pm - 11:20pm

ctDNA can predict overall survival in patients with advanced cutaneous melanoma
Presented by: Vinicius Vazquez

11:20pm - 11:35pm

Trial design and assay validation for the phase II/III DETECTION trial: Circulating tumor DNA guidEd
Therapy for stage IIB/C mElanoma after surgiCal resection
Presented by: Rebecca Lee

11:35am - 12:00pm

Slip versus Slop: A Head-to-Head Comparison of UV-Protective Clothing to Sunscreen
Presented by: Liz Berry

12:00pm - 12:25pm

Q&A

12:30pm - 2:00pm

Lunch - Exhibit and Poster Viewing
Cromdale Hall & Strathblane Hall

2:00pm - 4:03pm

CONCURRENT SESSION 3A - Melanoma Immune Modulators and Response - Session Chair - Goran Jonsson
Pentland Suite

2:00pm - 2:20pm

RNF5 and gut microbiome in anti-tumor and auto-immunity
Presented by: Ze'ev Ronai

2:20pm - 2:35pm

Distinct microbial communities play a role in melanoma brain metastasis
Presented by: Golnaz Morad

2:35pm - 2:50pm

The mucosal melanoma tumor microbiome is distinct from cutaneous with unfavorable
proportions of immune- associated species
Presented by: Pritika Parmar

2:50pm - 3:05pm

BRAFi+MEKi-mediated pyroptosis alters immune cell trafficking between the tumor and lymph node
Presented by: Nicole A.Wilski

3:05pm - 3:25pm

Multi-omic analysis of immune-related adverse events (irAEs) in melanoma patients (pts) treated with anti-PD1-based immune checkpoint inhibitors (ICIs)
Presented by: Florentia Dimitriou

3:25pm - 3:40pm

Melanosome as melanoma immune modulators
Presented by: Carmit Levy

3:40pm - 4:00pm

A revised classification of melanoma TILs informs patient outcomes and therapeutic strategies
Presented by: Niroshana Anandasabapathy

4:00pm - 4:03pm

Flash Talks

ZEB1 transcription factor promotes immune escape in melanoma
Presented by: Julie Caramel

2:00pm - 3:40pm

CONCURRENT SESSION 3B - Innovative Technologies - Session Chair - David Adams
Lomond Suite

2:00pm - 2:20pm

Personalised Immunotherapy Program (PIP): a multi-omic tool to predict the response of melanoma patients to anti-PD1-based immune checkpoint inhibitors.
Presented by: James Wilmott

2:20pm - 2:35pm

Defining tumor reactive T cells in uveal melanoma metastases
Presented by: Jonas A. Nilsson

2:35pm - 2:50pm

Spatially mapping the melanoma immune landscape of primary, regional, and brain metastases using Imaging Mass Cytometry
Presented by: Ian Watson

2:50pm - 3:05pm

Dissection of Melanoma-Microenvironment Interactions during Tumor Progression
Presented by: Giulia Lovati

3:05pm - 3:20pm

Short Talks

High-Throughput Screening Identifies Novel ROS-Inducing Small Molecules as a Therapy for Treatment- Resistant Melanoma
Presented by: Corinne I. Stoffel

LW-02 Column Immunopheresis® to Remove Soluble TNF Receptors: A Novel Immunotherapeutic Strategy for Melanoma and Other Solid Tumors
Presented by: Victoria Manax

Molecular analysis of tumor dormancy in a 3D printed melanoma model
Presented by: Sonja K. Schmidt

3:20pm - 3:40pm

Deep phenotyping and genetic susceptibility to melanoma
Presented by: Susana Puig

4:00pm - 4:15pm

Refreshment Break
Cromdale Hall & Strathblane Hall

4:15pm - 5:30pm

SMR Global Science Perspective

Click here to view this recording.

4:15pm - 4:25pm

Introduction and Vision
Presented by Daniela Robles-Espinoza

4:25pm - 4:40pm

Global Collaboration in Melanoma Modeling: A Case Study
Presented by: Chi-Ping Day

4:40pm - 4:55pm

Presented by: Gretchen Alicea 

4:55pm - 5:10pm

Modeling in vitro melanoma heterogeneity: redox, resistance and pigmentation profiles
Presented by: Silvya Maria-Engler

5:10pm - 5:20pm

Presented by: Vito Rebecca

5:20pm - 5:30pm

Discussion
Chaired by: Daniela Robles-Espinoza, Vito Rebecca

5:30pm - 7:00pm

Poster Reception
Cromdale Hall

7:00pm - 11:00pm

Trainee Night Out - BrewDog Bar